Press releases
Browse GSK global press releases issued since 2009. Search them by keyword or browse by year/business category.
Press releases issued by our local operating companies can be viewed on our market websites.
-
ViiV Healthcare receives complete response letter from US FDA for use of investigational cabotegravir and rilpivirine long-acting regimen in the treatment of HIV
ViiV Healthcare received a CRL from the FDA regarding its application for cabotegravir and rilpivirine.
-
GSK announces positive headline results in phase 3 study of Benlysta in patients with lupus nephritis
BLISS-LN achieves primary endpoint and all major secondary endpoints. On-track for regulatory submission during the first half of 2020.
-
Pivotal DREAMM-2 study demonstrated a clinically meaningful overall response rate with belantamab mafodotin (GSK2857916) for patients with relapsed/refractory multiple myeloma
Today announced treatment with the investigational single-agent belantamab mafodotin.
-
GSK Consumer Healthcare nutritional products divestment
GSK Consumer Healthcare nutritional products divestment
-
ViiV Healthcare files submissions to the FDA and EMA for the first-ever dispersible formulation of dolutegravir (DTG) for children living with HIV
If approved, DTG will be the first integrase inhibitor available as a dispersible tablet for children living with HIV.
-
ViiV Healthcare submits New Drug Application to the FDA for fostemsavir, an investigational, first-in-class attachment inhibitor for the treatment of HIV in adults with few treatment options available
ViiV Healthcare completed submission of a New Drug Application (NDA) to the US Food and Drug Administration (FDA).
-
ViiV Healthcare announces exclusive licensing agreement with the National Institutes of Health for investigational “bNAb” with potential for long-acting HIV treatment and prevention
ViiV Healthcare announces exclusive licensing agreement with the National Institutes of Health for investigational “bNAb”.
-
Nucala (mepolizumab) is the first treatment to show a significant reduction in flares for patients with Hypereosinophilic Syndrome (HES)
Positive data from a pivotal study supports new regulatory filing in HES
-
EACS 2019: ViiV Healthcare to present 17 abstracts from its portfolio addressing the diverse needs of people living with HIV
Data presentations expand understanding of ViiV Healthcare’s pipeline for heavily treatment-experienced populations.
-
GSK delivers sales of £9.4 billion +16% AER, +11% CER (Pro-forma +6% CER*)
GSK delivers sales of £9.4 b +16% AER, +11% CER (Pro-forma +6% CER*) Total EPS 31.4p +9% AER, -1% CER; Adjusted EPS 38.6p +9% AER, +1% CER
-
Intravenous Benlysta is the first biologic treatment to be approved for children with lupus in Europe
European Commission has made a decision to extend to children five years and older, the existing adult indication for intravenous Benlysta
-
GSK candidate vaccine demonstrates sustained level of protection against active pulmonary tuberculosis
Analysis of phase IIb study published in the New England Journal of Medicine, presented at the 50th Union World Conference on Lung Health.
-
GSK starts a phase III clinical programme for a potential first-in-class antibiotic, gepotidacin
First in a new chemical class of antibiotic with a mechanism of action distinct from any currently approved antibiotic.
-
GSK agrees to divest rabies and tick-borne encephalitis vaccines to Bavarian Nordic
GSK to receive upfront payment of approximately EUR301 million and milestone payments for a total consideration of up to EUR955 million
-
Global Fund Replenishment - 2019 media statement
The Global Fund, world's largest financier of 3 of the deadliest diseases worldwide, AIDS, TB, and malaria, has helped save 27 million lives
-
GSK and Lyell Immunopharma join forces to develop the next generation of cancer cell therapies
Collaboration will combine Lyell’s technologies with GSK’s pipeline of cell therapies and manufacturing capability
-
GSK submits filing to FDA for Trelegy Ellipta use in patients with asthma
Trelegy Ellipta was approved in the US in September 2017 for the treatment of patients with Chronic Obstructive Pulmonary Disease (COPD).
-
IDWeek 2019: ViiV Healthcare to present 20 abstracts from its innovative R&D portfolio with focus on 2-drug and long-acting regimens and mental health impact of HIV
Presentations include six-year data for the investigational regimen of cabotegravir and rilpivirine.
-
Nucala significantly reduces exacerbations in first global prospective real-world study of a biologic in severe eosinophilic asthma
Results from interim analysis of REALITI-A study presented at ERS conference
-
Phase 3 PRIMA trial of Zejula® (niraparib) is the first study to show a PARP inhibitor significantly improves PFS, regardless of biomarker status, when given as monotherapy in women with first-line platinum responsive advanced ovarian cancer
Niraparib treatment resulted in a 38% reduction in the risk of disease progression or death in the study population compared to placebo.